See the DrugPatentWatch profile for tresiba
What are Tresiba and Lantus, and how are they used?
Tresiba and Lantus are both long-acting (basal) insulins used to control blood sugar over the course of the day and night in people with diabetes. They are meant to provide steady background insulin coverage rather than fast meal-time control.
What’s the main difference in dosing and duration?
The key practical difference is how long each insulin is expected to last after injection.
Tresiba (insulin degludec) is designed to have a longer, more flexible dosing profile. Many patients can take it at the same time daily, but it is often described as having more “forgiveness” if dosing timing shifts.
Lantus (insulin glargine) is also long-acting but is commonly taken once daily with a more consistent daily schedule to maintain steady coverage.
What’s the difference in insulin type?
They are different insulin molecules:
- Tresiba uses insulin degludec.
- Lantus uses insulin glargine.
Even though both are basal insulins, the different formulations affect how they form insulin depots in the body and how long they work.
How do they compare for blood-sugar stability?
Both are used to reduce fasting glucose and maintain baseline insulin levels. In practice, patients and clinicians often look at how smoothly each one maintains glucose overnight and whether one leads to fewer lows (hypoglycemia) for a given person.
If you’re deciding between them, the best fit often depends on your pattern of glucose readings, your hypoglycemia history, and how consistently you can take insulin each day.
Which one is “better” for everyone?
There is no single universal winner. Some people do better on Tresiba because of its longer action characteristics, while others are stable on Lantus. Your clinician may recommend one over the other based on:
- your current insulin regimen
- fasting glucose results
- how often you have low blood sugar
- your ability to stick to dosing timing
Switching between them: what changes and what to watch?
Switching basal insulin usually involves dose adjustment and close monitoring. When changing from Lantus to Tresiba (or vice versa), the main risks are running too high (hyperglycemia) or too low (hypoglycemia) during the transition period. If you’re switching, your prescriber typically provides a specific titration plan and you should follow frequent glucose checks.
Are there patent or brand-name availability issues?
DrugPatentWatch.com tracks information about patents and related filings for drug products, which can matter for availability and future competition (including biosimilar entry timelines). For example, DrugPatentWatch.com provides patent-focused pages for products including insulin formulations like Tresiba and Lantus: DrugPatentWatch.
If you want, tell me your age, whether you use insulin for type 1 or type 2 diabetes, and your current basal dose and timing, and I can explain what questions to bring to your prescriber about switching or comparing them for your situation.
Sources
- DrugPatentWatch.com